Becker's Healthcare November 18, 2024
As President-elect Donald Trump prepares to take office, the future of Medicare’s drug price negotiation program, part of the 2022 Inflation Reduction Act, is uncertain, Roll Call reported Nov. 15.
The program, which allows the federal government to negotiate prices for high-cost drugs, is a key policy achievement of the Biden administration, but its future could be affected by changes under the new administration and Congress.
Here are four more things to know:
- Upon taking office, the Trump administration will be responsible for implementing the Medicare price negotiation program, which allows the government to negotiate prices on certain drugs starting in 2026. While Mr. Trump has previously supported Medicare price negotiations, his position on the current program...
Today's Sponsors
Today's Sponsor